NasdaqGS:TXGLife Sciences
A Fresh Look at 10x Genomics’s (TXG) Valuation After PERIBLOOD Trial Launch and Mixed Analyst Signals
If you have been watching 10x Genomics (TXG), the latest developments likely caught your eye. This week brought a mix of cautious optimism and long-term intrigue. On one hand, fresh coverage from Piper Sandler underscored 10x Genomics’ leadership in single-cell analysis, but also warned about near-term price pressure and softer market conditions. In the same breath, 10x Genomics announced the launch of its high-profile PERIBLOOD clinical trial, an ambitious international collaboration that...